Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03599765 |
Title治疗寡转移性实体瘤患者的全身疗法与局部巩固疗法 | 阶段
第二阶段
|
Date Added 2018-07-26 |
地点
Arizona, United States
Arkansas, United States Hawaii, United States Michigan, United States New Jersey, United States Ohio, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03577665 |
Title为结直肠癌肝转移患者提供治愈性质子束疗法 | 阶段
不适用
|
Date Added 2018-07-05 |
地点
大韩民国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03568058 |
TitlePersonalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | 阶段
第 1 阶段
|
Date Added 2018-06-26 |
地点
California, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Pembrolizumab, personalized vaccine, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT03566355 |
TitleCurative Proton Beam Therapy for Patients With Lung Metastasis of Colorectal Cancer | 阶段
不适用
|
Date Added 2018-06-25 |
地点
大韩民国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03547999 |
TitleA Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | 阶段
第二阶段
|
Date Added 2018-06-06 |
地点
California, United States
Florida, United States Kansas, United States New Jersey, United States Ohio, United States Oregon, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
FPV-CV301, mFOLFOX6, MVA-BN-CV301, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT03545815 |
Title对间皮素阳性多发性实体瘤患者进行的 CRISPR-Cas9 介导的 PD-1 和 TCR 基因敲除间皮素定向 CAR-T 细胞研究。 | 阶段
第 1 阶段
|
Date Added 2018-06-04 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
抗间皮素 CAR-T 细胞 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03530397 |
Title在晚期实体瘤受试者中评估 MEDI5752 的研究 | 阶段
第 1 阶段
|
Date Added 2018-05-21 |
地点
Michigan, United States
New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States 澳大利亚 法国 意大利 大韩民国 荷兰 葡萄牙 西班牙 台湾 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Carboplatin, MEDI5752, Pembrolizumab, Pemetrexed, Alimta, Imfinzi, Keytruda, Paraplatin |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03519412 |
TitlePembrolizumab 在 MMR 精通的转移性结直肠癌中的药理作用触发高突变状态 | 阶段
第二阶段
|
Date Added 2018-05-09 |
地点
意大利
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
pembrolizumab (treatment), temozolomide (induction),, Keytruda, Temodar |
标签
MSS/ MMRp
|
| NCT ID NCT03502733 |
TitleTesting the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma | 阶段
第 1 阶段
|
Date Added 2018-04-19 |
地点
Maryland, United States
Texas, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Copanlisib, Ipilimumab, Nivolumab, Aliqopa, Opdivo |
标签
MSS/ MMRp
|
| NCT ID NCT03494946 |
Title结直肠癌患者肝移植与化疗的比较 | 阶段
不适用
|
Date Added 2018-04-11 |
地点
挪威
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
化疗 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
